A dual incretin research peptide is a synthetic compound that activates both GLP-1R and GIPR simultaneously
Luft jedes Mal gleich gut
The identification of dysregulated incretin secretion and action in both obesity and diabetes led to the revolutionary discovery of incretin-based drugs, such as glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) and dual glucose-dependent insulinotropic peptide (GIP)/GLP-1 RAs [24,25,26,27,28]
This can be a misleading as lecithin extract is actually a complex mixture of phospholipids, glycolipids, and triglycerides, containing less than 20% total phosphatidylcholine composition
Therapeutic strategies targeting the gut microbiota include conventional probiotics, prebiotics, and fecal microbiota transplantation, alongside emerging synthetic biology approaches employing genetically engineered probiotic strains to deliver bioactive molecules, including GLP-1, directly in the gut microenvironment